Last year, studies suggested that lenacapavir, already used to treat people with HIV, was nearly 100% effective in stopping transmission in both women and men.

The owner of the United States' largest pharmacy benefit manager (PBM) is declining to cover Gilead Sciences’ long-acting HIV ...

Advocates for HIV prevention are calling a newly approved injectable medication a major step in eliminating the spread of the ...

Studies done in various countries, including South Africa, have shown that lenacapavir is highly effective for HIV prevention.

Lenacapavir, an antiretroviral drug typically used to treat HIV infections, can also effectively prevent them, a phase 3 clinical trial has shown.

“Lenacapavir represents a major scientific advance — it’s the first long-acting injectable HIV prevention strategy that requires dosing just twice a year,” according to Paul E. Sax, MD ...

Kenya is one of nine African countries selected for the initial rollout of lenacapavir (LEN), a new injectable drug for human ...

Lenacapavir’s capsid inhibition is relatively less understood compared to mechanisms of other approved approaches in HIV. However, the capsid protein is essential for viral entry and hence ...

While lenacapavir does cost around $40,000 per patient per year in the U.S., this is the price for the drug when it is used as an HIV therapy, Blair Baumwell, a spokesperson for the company that ...

Lenacapavir is given in two injections that have to be delivered subcutaneously, something that “takes training and time” to learn, National Institute of Allergy and Infectious Diseases ...

Twice-Yearly Lenacapavir Demonstrates Sustained Impact on Health-Related Quality of Life in People With HIV – Patient-Reported Outcomes From the CAPELLA Trial Align With the Demonstrated Safety ...

Lenacapavir showed a 96% reduction in HIV infections, outperforming daily F/TDF in the PURPOSE 2 trial. The trial included a diverse global population, with 67% non-White participants, enhancing ...